Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin C for epigenetic effects in patients with germline TET2 mutation
2018-000155-41Phase 2Completed
- Sponsor
- University of Helsinki
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ascorbic acid in familial cancer syndrome (FCS), sponsored by University of Helsinki. Primary endpoint: Stage of hypermethylation. Started Jan 2019; status: completed.
02
Drugs
ascorbic acid
03
Conditions
familial cancer syndrome (FCS)
Beyond the preview
Go deeper on 2018-000155-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000155-41.